Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 242

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 8
Chunk 242
---
Item 8. Financial Information

A. Consolidated Statements and Other Financial Information.

Consolidated Financial Statements

Our consolidated financial statements are included as part of this Annual Report, starting at page F-1.

Legal Proceedings

From time to time, the Company may be involved in various claims and legal proceedings relating to claims arising out of our operations. The Company is not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors.

With respect to an arbitral decision rendered in December 2021 relating to milestone payments received by the Company under the collaboration and option agreement that the Company signed the 2018 AZ Option Agreement, see Note 6 to the consolidated financial statements included as part of this Annual Report.

Dividend Policy

The Company has never declared or paid any dividends on our ordinary shares. The Company does not anticipate paying cash dividends on our equity securities in the foreseeable future and intends to retain all available funds and any future earnings for use in the operation and expansion of our business, given our state of development.

Subject to the requirements of French law and our bylaws, dividends may only be distributed from our distributable profits, plus any amounts held in our available reserves which are reserves other than legal and statutory and revaluation surplus. Dividend distributions, if any in the future, will be made in euro and converted into U. S. dollars with respect to the ADSs, as provided in the deposit agreement. See the information set forth in our prospectus dated October 16, 2019, filed with the SEC pursuant to Rule 424(b), under the heading “ Description of Share Capital” for more information.

B. Significant Changes.

Not applicable.

Item 9. The Offer and Listing.